We show that CTX-MMAE is well-tolerated and specifically targets EGFR to elicit dose-dependent therapeutic effects in two distinct models of PaCa that harbour KRAS mutations, which render them refractory to standard EGFR-targeted therapies. The gene discussed is KRAS; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.